
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Take our latest poll and let us know if you have seen an increase in a requests for the MMR vaccine in the wake of the current measles epidemic.






